| 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors AH Long, WM Haso, JF Shern, KM Wanhainen, M Murgai, M Ingaramo, ... Nature medicine 21 (6), 581-590, 2015 | 1649 | 2015 |
| CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy TJ Fry, NN Shah, RJ Orentas, M Stetler-Stevenson, CM Yuan, ... Nature medicine 24 (1), 20-28, 2018 | 1281 | 2018 |
| Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors JF Shern, L Chen, J Chmielecki, JS Wei, R Patidar, M Rosenberg, ... Cancer discovery 4 (2), 216-231, 2014 | 715 | 2014 |
| The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation AS Brohl, DA Solomon, W Chang, J Wang, Y Song, S Sindiri, R Patidar, ... PLoS genetics 10 (7), e1004475, 2014 | 431 | 2014 |
| CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity E Jacoby, SM Nguyen, TJ Fountaine, K Welp, B Gryder, H Qin, Y Yang, ... Nature communications 7 (1), 12320, 2016 | 414 | 2016 |
| PAX3–FOXO1 establishes myogenic super enhancers and confers BET bromodomain vulnerability BE Gryder, ME Yohe, HC Chou, X Zhang, J Marques, M Wachtel, ... Cancer Discovery 7 (8), 884-899, 2017 | 273 | 2017 |
| Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22 H Qin, S Ramakrishna, S Nguyen, TJ Fountaine, A Ponduri, ... Molecular Therapy-Oncolytics 11, 127-137, 2018 | 243 | 2018 |
| The SS18-SSX fusion oncoprotein hijacks BAF complex targeting and function to drive synovial sarcoma MJ McBride, JL Pulice, HC Beird, DR Ingram, AR D’Avino, JF Shern, ... Cancer cell 33 (6), 1128-1141. e7, 2018 | 220 | 2018 |
| KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis M Murgai, W Ju, M Eason, J Kline, DW Beury, S Kaczanowska, ... Nature medicine 23 (10), 1176-1190, 2017 | 193 | 2017 |
| ADP-ribosylation factors (ARFs) and ARF-like 1 (ARL1) have both specific and shared effectors: characterizing ARL1-binding proteins H Van Valkenburgh, JF Shern, JD Sharer, X Zhu, RA Kahn Journal of Biological Chemistry 276 (25), 22826-22837, 2001 | 184 | 2001 |
| Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma H Shalabi, IL Kraft, HW Wang, CM Yuan, B Yates, C Delbrook, ... Haematologica 103 (5), e215, 2018 | 156 | 2018 |
| Modulation of target antigen density improves CAR T-cell functionality and persistence S Ramakrishna, SL Highfill, Z Walsh, SM Nguyen, H Lei, JF Shern, H Qin, ... Clinical Cancer Research 25 (17), 5329-5341, 2019 | 145 | 2019 |
| MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma ME Yohe, BE Gryder, JF Shern, YK Song, HC Chou, S Sindiri, A Mendoza, ... Science translational medicine 10 (448), eaan4470, 2018 | 135 | 2018 |
| Genomic classification and clinical outcome in rhabdomyosarcoma: a report from an international consortium JF Shern, J Selfe, E Izquierdo, R Patidar, HC Chou, YK Song, ME Yohe, ... Journal of Clinical Oncology 39 (26), 2859-2871, 2021 | 133 | 2021 |
| Histone hyperacetylation disrupts core gene regulatory architecture in rhabdomyosarcoma BE Gryder, S Pomella, C Sayers, XS Wu, Y Song, AM Chiarella, S Bagchi, ... Nature genetics 51 (12), 1714-1722, 2019 | 133 | 2019 |
| Chemical genomics reveals histone deacetylases are required for core regulatory transcription BE Gryder, L Wu, GM Woldemichael, S Pomella, TR Quinn, PMC Park, ... Nature communications 10 (1), 3004, 2019 | 130 | 2019 |
| Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534) SQ Li, AT Cheuk, JF Shern, YK Song, L Hurd, H Liao, JS Wei, J Khan PloS one 8 (10), e76551, 2013 | 116 | 2013 |
| MultiDimensional ClinOmics for precision therapy of children and adolescent young adults with relapsed and refractory cancer: a report from the center for cancer research W Chang, AS Brohl, R Patidar, S Sindiri, JF Shern, JS Wei, YK Song, ... Clinical cancer research 22 (15), 3810-3820, 2016 | 110 | 2016 |
| Pediatric rhabdomyosarcoma JF Shern, ME Yohe, J Khan Critical Reviews™ in Oncogenesis 20 (3-4), 2015 | 109 | 2015 |
| ARL2 and BART enter mitochondria and bind the adenine nucleotide transporter JD Sharer, JF Shern, H Van Valkenburgh, DC Wallace, RA Kahn Molecular biology of the cell 13 (1), 71-83, 2002 | 108 | 2002 |
Javed KhanDeputy Branch Chief Genetics Branch, Senior Investigator, Center for Cancer Research, NCI, NIH在 mail.nih.gov 的电子邮件经过验证
